Overview

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Status:
Active, not recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Phase:
Phase 3
Details
Lead Sponsor:
BeiGene